factor (G-CSF), according to recommended dosage 1 (5 μg/ kg/day = 50 μg Neupogen ® /day), for seven consecutive days, without effect on his neutrophil levels but for a marked increase in his eosinophil counts: 2.2 × 10 9 /L (ageadjusted range: <0.05 × 10 9 /L). A bone marrow biopsy showed lively erythropoiesis, normal thrombocytopoiesis, inhibited neutropoiesis, normal eosinophilopoiesis, and no signs of neoplastic hematologic disease. A possible cellulitis, located to his left instep, responded to amoxicillin and clavulanic acid. After discharge from the hospital, he was given preventive amoxicillin. In the following 10 months, his main complaints were gingivitis, oral ulcers, and mucocutaneous candidiasis, the latter amenable to oral antifungals. Figure 1 ) and prophylactic sulfamethoxazole with trimethoprim, our patient, aged three years and 6 months, underwent successful allogeneic bone marrow transplantation. Written consent by the patient's parents and permission from the chairman of the Regional Committee on Health Research Ethics for Southern Denmark (case S-20192000-48) was obtained.
| DISCUSSION
Neutropenia affects approximately two-thirds of patients with CD40L deficiency, leading to significant comorbidity due to mucocutaneous inflammation. 3 The pathogenesis underlying CD40L deficiency associated neutropenia has not yet been clearly delineated. As bone marrow stromal cells express CD40, 4 stimulation by CD40L can induce them to produce G-CSF. 5 Hence, CD40L deficiency could compromise the ability of bone marrow stromal cells to secrete G-CSF, thereby causing neutropenia. Supporting that hypothesis, treatment with G-CSF has been reported to increase or normalize the neutrophil counts in CD40L deficiency. 6 However, seven days of treatment with a standard dosage of G-CSF did not affect our patient's neutropenia but instead markedly increased his peripheral eosinophil concentration, indicating that the G-CSF levels were sufficient to induce myelopoietic lineage differentiation. Still, we cannot exclude that the standard G-CSF dosage was insufficient, since the patient, despite the presence of antineutrophil antibodies, experienced a pronounced, possibly reactive, neutrophil increase, consistent with G-CSF responsiveness. Infection-induced G-CSF secretion results in massive bone marrow neutrophil release 7 which may override the effects of neutrophil antibodies. Hence, pronounced bone marrow release of neutrophils, secondary to infection, may have effected our patient's transiently normalized neutrophil count in the presence of neutrophil auto-antibodies. Theoretically, our patient could have experienced additional unrecorded instances of normalized neutrophil concentrations, however, his prolonged clinical complaints, involving gingivitis, oral ulcers, and mucocutaneous candidiasis, indicated sustained neutropenia. The clinical efficacy of IVIG, in treating CD40L deficiency associated neutropenia, 8 suggests that autoimmune mechanisms might also be involved, although autoimmune neutropenia has never been confirmed in this disorder 8 and some authors even mention it as unlikely. 9 We hereby represent the first case of CD40L deficiency, accompanied by undetectable plasma IgG and IgA concentrations, but where free and cell-bound antineutrophil IgG antibodies coincided with a protracted, clinically significant neutropenia. We were not able to determine the subclass specificity of these IgG antibodies, but to varying degrees all IgG subclasses may engage Fc-receptors and thereby contribute to splenic opsonization of antibody-coated neutrophils. The mechanism (s) underlying our patient's sparse production of IgG is uncertain. However, CD40L independent production of IgG toward viral glycoproteins has been documented 10 production. Interestingly, Litinskiy et al 13 have demonstrated that human dendritic cells can induce CD40L independent IgG class shift through expression of the B-cell stimulator proteins: B-cell activating factor of the tumor-necrosis-factor family (BAFF) and a proliferation-inducing ligand (APRIL). We were not able to confirm the antigen specificity of the IgG antibodies, however, we cannot preclude that the antibodies were "neutrophil specific" as other autoantigen specificities were not detected (no thrombocytopenia, the patient was DAT negative and we observed no ANA reactivity). However, the lack of any known neutrophil antigen specificity of these antibodies concurred with our patient's severely reduced SHM, as CD40L is crucial for SHM. Auto-reactivity is often a feature of compromised SHM, since inherently auto-reactive B-cell clones are prevented from rescuing themselves, through the process of SHM, from auto-reactivity, a process called "clonal redemption". 14 
| CONCLUSION
We present a case of CD40L deficiency where the presence of neutrophil reactive IgG coincided with a clinically severe neutropenia. Due to its diverse immunomodulatory capabilities, IVIG therapy is widely used for treating autoimmune disorders. Our case suggests a mechanistic rationale for the clinical efficacy of IVIG in attenuating CD40L deficiency associated neutropenia and substantiates models showing that the requirement for CD40L, in mediating B-cell IgG isotype switching, can be circumvented.
